| Mark J Hudson, MD | |
|
347 North Smith Ave, 401, St Paul, MN 55102 | |
| (651) 220-6750 | |
| (651) 220-6770 |
| Full Name | Mark J Hudson |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 347 North Smith Ave, St Paul, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962463547 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 45433 (Minnesota) | Primary |
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Standard Review designation to the New Drug Application (NDA) for carfilzomib for the potential treatment of patients with relapsed and refractory multiple myeloma.
Infants whose mothers were obese during pregnancy may have a heightened risk of developing colorectal cancer later in life, according to new research led by public health experts at The University of Texas Health Science Center at Houston.
Progress toward understanding the role of sex hormones in the growth of prostate cancer—the most common cancer in U.S. men—has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.
Use of a score based on the amount of calcium in coronary arteries in addition to traditional risk factors improved the classification of risk for prediction of coronary heart disease events, and placed more individuals in the most extreme risk categories, according to a study in the April 28 issue of JAMA.
› Verified 3 days ago
| Entity Name | Children's Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932208808 PECOS PAC ID: 2668370966 Enrollment ID: O20040406000939 |
News Archive
Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Standard Review designation to the New Drug Application (NDA) for carfilzomib for the potential treatment of patients with relapsed and refractory multiple myeloma.
Infants whose mothers were obese during pregnancy may have a heightened risk of developing colorectal cancer later in life, according to new research led by public health experts at The University of Texas Health Science Center at Houston.
Progress toward understanding the role of sex hormones in the growth of prostate cancer—the most common cancer in U.S. men—has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.
Use of a score based on the amount of calcium in coronary arteries in addition to traditional risk factors improved the classification of risk for prediction of coronary heart disease events, and placed more individuals in the most extreme risk categories, according to a study in the April 28 issue of JAMA.
› Verified 3 days ago
| Entity Name | Hennepin Healthcare System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033138136 PECOS PAC ID: 4789684861 Enrollment ID: O20070207000467 |
News Archive
Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Standard Review designation to the New Drug Application (NDA) for carfilzomib for the potential treatment of patients with relapsed and refractory multiple myeloma.
Infants whose mothers were obese during pregnancy may have a heightened risk of developing colorectal cancer later in life, according to new research led by public health experts at The University of Texas Health Science Center at Houston.
Progress toward understanding the role of sex hormones in the growth of prostate cancer—the most common cancer in U.S. men—has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.
Use of a score based on the amount of calcium in coronary arteries in addition to traditional risk factors improved the classification of risk for prediction of coronary heart disease events, and placed more individuals in the most extreme risk categories, according to a study in the April 28 issue of JAMA.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark J Hudson, MD 2910 Centre Pointe Dr, 35-121a, Roseville, MN 55113 Ph: (651) 855-2327 | Mark J Hudson, MD 347 North Smith Ave, 401, St Paul, MN 55102 Ph: (651) 220-6750 |
News Archive
Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Standard Review designation to the New Drug Application (NDA) for carfilzomib for the potential treatment of patients with relapsed and refractory multiple myeloma.
Infants whose mothers were obese during pregnancy may have a heightened risk of developing colorectal cancer later in life, according to new research led by public health experts at The University of Texas Health Science Center at Houston.
Progress toward understanding the role of sex hormones in the growth of prostate cancer—the most common cancer in U.S. men—has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.
Use of a score based on the amount of calcium in coronary arteries in addition to traditional risk factors improved the classification of risk for prediction of coronary heart disease events, and placed more individuals in the most extreme risk categories, according to a study in the April 28 issue of JAMA.
› Verified 3 days ago
Yoav H Messinger, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 347 North Smith Avenue, St Paul, MN 55102 Phone: 651-220-6732 Fax: 651-220-6005 | |
Kimberly K Rathmann, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 451 North Dunlap Street, Mail Stop 32700a, St Paul, MN 55104 Phone: 651-999-4700 Fax: 651-999-4781 | |
Krishna M Saxena, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Children's Specialty Clinic-diabetes/endocrinology-stpl, 347 North Smith Avenue, St Paul, MN 55102 Phone: 651-220-6818 Fax: 651-220-6064 | |
Dr. Carolyn J Levitt, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 347 North Smith Avenue, 401, Midwest Childrens Resource Center, St Paul, MN 55102 Phone: 651-220-6750 Fax: 651-220-6770 | |
Sylvia M Sekhon, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2500 Como Avenue, Mail Stop 31100a, St Paul, MN 55108 Phone: 651-641-6200 Fax: 651-641-6205 | |
Susan C Goodale, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 393 N Dunlap St, Suite 300, St Paul, MN 55104 Phone: 651-645-4693 Fax: 651-645-6503 | |
Richard D Andersen, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 347 N Smith Ave, Childrens Specialty Clinic Infectious Diseases Stpl, St Paul, MN 55102 Phone: 651-220-6444 Fax: 651-220-7233 |